A Phase 2/3 interventional study of Bifidobacterium lactis HN019 and Bifidobacterium lactis HN019 in Gastrointestinal Symptoms, sponsored by Fonterra Research Centre. Completed. Open to participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-07-28.
Sponsored by Fonterra Research Centre · Phase 2/3, Interventional, and Supportive care
The purpose of this study was to investigate the dose response effect of Bifidobacterium lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms.
Fonterra Research Centre is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Bifidobacterium lactis HN019, 10 billion cfu/day
Dietary Supplement: Bifidobacterium lactis HN019
Bifidobacterium lactis HN019, 1 billion cfu/day
Dietary Supplement: Bifidobacterium lactis HN019
Placebo
Dietary Supplement: Placebo
Bifidobacterium lactis HN019, 10 billion cfu/day, once a day for 14 days
Bifidobacterium lactis HN019, 1 billion cfu/day, once a day for 14 days
Placebo, once a day for 14 days
Colonic transit time
Time frame: 14 days
Gastrointestinal symptoms
Time frame: 14 days
No study locations are listed for this record.
This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fonterra Research Centre